BioSpace News Archive

Dr. Howard Njoo, Canada’s Deputy Chief Public Health Officer and Interim Vice-President of the Infectious Diseases Programs Branch, announced funding to support a pan-Canadian study of the clinical and functional outcomes of adults and children who experienced myocarditis and/or pericarditis after receiving an mRNA COVID-19 vaccination.

Monteris Medical, a private medical technology company dedicated to becoming the technology leader in minimally invasive brain surgery, announced it has secured $73 million in financing including $35 million in new Series D equity and a $38 million debt facility.

Centinel Spine®, LLC, (“the Company”) a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced the 100th completed procedure in the United States with its prodisc® C Vivo Cervical Total Disc Replacement (TDR) product.

Geistlich Pharma North America announced today the acquisition of Lynch Biologics, LLC, the developer and sole provider of GEM 21S®, the first recombinant growth factor product for use in oral regenerative surgery.

Thermo Fisher Scientific has upgraded its leading Applied Biosystems Chromosome Analysis Suite (ChAS) software through a collaboration with Genoox, a community-driven genomic data company.

Allurion, a company dedicated to ending obesity, has received approval to launch its revolutionary gastric balloon technology in Brazil.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark”) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) cells using an ionizable lipid nanoparticle

Urovant Sciences today announced the recent publication of a Phase 1 study of the pharmacokinetic profile of GEMTESA (vibegron) 75mg in the peer-reviewed journal, Clinical Pharmacology in Drug Development. In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.

The American Diabetes Association® announced its recognition as a winner in the 2022 Sharecare Awards in the category of chronic diseases for The Big Step Up: Detection that encourages people to take the big step up for their health.

October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for new second-line indication of YIKAIDA submitted by Fosun Kite Biotechnology Co., Ltd. (hereinafter referred to as Fosun Kite) was approved for review and included in the list for priority review.